A Asia Pacific Bioprocessing Market Forecast to 2031 - Regional Analysis - by Product (Instruments and Consumables & Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess)

Asia Pacific Bioprocessing Market Forecast to 2031 - Regional Analysis - by Product (Instruments and Consumables & Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell & Gene Therapy, and Others), and End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others)

The Asia Pacific bioprocessing market was valued at US$ 5,488.87 million in 2023 and is expected to reach US$ 16,868.77 million by 2031; it is estimated to register a CAGR of 15.1% from 2023 to 2031.

Proliferating Demand for Personalized Medicine Boosts Asia Pacific Bioprocessing Market

The transformation of the healthcare industry from one-size-fits-all to a targeted approach is expanding the demand for personalized medicine. Precision medicine is being considered as one of the most promising approaches to tackle health concerns such as cancer, neurodegenerative diseases, and rare genetic conditions. Innovations in the production of personalized medicines are likely to impact the entire sector, and single-use technologies aimed at smaller-volume production have potential applications in protein bioproduction, particularly in downstream processes. Personalized and differentiated approaches to medicine are leading to a need for a wider range of products-many of them for a relatively small group of patients. Therefore, a fundamentally different approach to the production and delivery of biological products may be required. Precision medicine utilizes the genomic information of an individual to offer targeted treatment for a particular indication. The growing number of orphan diseases has increased the demand for biologics and drugs, which has subsequently boosted the growth of personalized medicines. In 2019, the FDA approved ~12 personalized medications for addressing the root causes of disease and further integrated precision medicine with clinical care. Also, increasing government efforts are strengthening personalized medicine research activities. For instance, in February 2020, the National Human Genome Research Institute (NHGRI) announced to establish a new precision medicine and genomics program. This program focuses on the innovation of genomics and informatics tools for better diagnosis and treatment of disease. Personalized medicines leverage advances in genetics and bioinformatics to target specific patient populations and treat previously untreatable diseases. Personalized medicine uses bioprocessing techniques to develop tailored therapies. From isolating specific cells to developing patient-specific treatments, bioprocessing steps are essential for producing treatments tailored to each patient. Therefore, the rising demand for personalized medicine is predicted to offer significant growth opportunities to the players operating in the bioprocessing market during the forecast period.

Asia Pacific Bioprocessing Market Overview

The Asia Pacific bioprocessing market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth in these countries is attributed to the rising chronic disease prevalence and favorable reimbursement policies. Moreover, expansion and product launch strategies implemented by market players are expected to contribute to the growth of the bioprocess technology market in the region. China accounted for the largest share of the market in 2023, and India is expected to record a significant CAGR in the market during the forecast period. The biopharmaceutical industry in China is undergoing a tremendous shift, evolving from a generic-focused landscape to a thriving innovation hub. Additionally, progress in industrialization and the application of novel drugs, high-end medical devices, and techniques contribute to the bioprocessing market growth in China. Thus, an increasing number of research centers, rising government funding, and constant initiatives taken by the market players for geographic expansion fuel the bioprocessing market growth in Asia Pacific.

Asia Pacific Bioprocessing Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Bioprocessing Market Segmentation

The Asia Pacific bioprocessing market is categorized into product, scale of operation, process, application, end user, and country.

Based on product, the Asia Pacific bioprocessing market is bifurcated into instruments and consumables & accessories. The instruments segment held a larger market share in 2023. Furthermore, the instruments segment is sub segmented into filtration devices, bioreactors, chromatography systems, centrifuge, drying devices, and others. Additionally, the bioreactors subsegment is categorized into pilot scale, full scale, and laboratory scale. Furthermore, the subsegment chromatography systems is segmented into liquid chromatography, gas chromatography, and others. Additionally, the consumables & accessories segment is sub segmented into reagents, cell culture media, chromatography resins, and others.

In terms of scale of operation, the Asia Pacific bioprocessing market is bifurcated into commercial operations and clinical operations. The commercial operations segment held a larger market share in 2023.

By process, the Asia Pacific bioprocessing market is bifurcated into downstream bioprocess and upstream bioprocess. The downstream bioprocess segment held a larger market share in 2023.

Based on application, the Asia Pacific bioprocessing market is categorized into monoclonal antibodies, vaccines, recombinant protein, cell & gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of end user, the Asia Pacific bioprocessing market is categorized into biopharmaceutical companies, contract manufacturing organization, and others. The biopharmaceutical companies segment held the largest market share in 2023.

By country, the Asia Pacific bioprocessing market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific bioprocessing market share in 2023.

Getinge AB, Thermo Fisher Scientific Inc, Sartorius AG, Corning Inc, Bio-Rad Laboratories Inc, Merck KGaA, 3M Co, Eppendorf SE, Repligen Corp, Entegris Inc, Agilent Technologies Inc, and Cytiva US LLC. are some of the leading companies operating in the Asia Pacific bioprocessing market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific bioprocessing market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific bioprocessing market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific bioprocessing market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.